Want to see IN:HIKAL full AI Analyst Report?
HIKAL Stock Chart & Stats
₹217.20
₹4.58(2.11%)
At close: 4:00 PM EDT
₹217.20
₹4.58(2.11%)
Day’s Range― - ―
52-Week Range₹145.95 - ₹307.50
Previous CloseN/A
Volume197.35K
Average Volume (3M)34.88K
Market Cap
₹27.31B
Enterprise Value₹34.81K
Total Cash (Recent Filing)₹138.00M
Total Debt (Recent Filing)₹6.84B
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.45%
Share Statistics
EPS (TTM)-3.96
Shares Outstanding123,300,750
10 Day Avg. Volume44,586
30 Day Avg. Volume34,881
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.51
Price to Sales (P/S)1.06
P/FCF Ratio20.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.1
Revenue Forecast (FY)₹19.62B
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive operating and free cash flow even in a loss-making year shows the business converts revenue into cash. That supports near-term debt servicing, working-capital needs and selective reinvestment without immediate external financing, enhancing operational resilience.
Manageable LeverageA meaningful reduction in total debt and modest leverage versus assets improves balance-sheet flexibility. Lower gross leverage reduces refinancing pressure, gives room for capex or strategic spend, and enhances resilience to cyclical swings in pharma and agro demand.
Specialty CDMO ModelA B2B specialty chemicals and CDMO model builds long-lived customer ties, technical barriers and repeat revenue from approved-supplier status. Serving pharma and agro markets diversifies end-market risk and leverages process chemistry capabilities for sustained contract opportunities.
Bears Say
Profitability DeteriorationNet losses signal operating and/or SG&A pressures that erode the firm's ability to internally fund growth and cushion shocks. Persistent losses can weaken supplier/customer confidence, limit R&D or capacity investments, and raise the risk of future balance-sheet stress if not reversed.
Inconsistent Revenue TrendsErratic top-line performance reduces visibility for capacity planning and weakens economies of scale in manufacturing. For a contract-driven CDMO, inconsistent volumes undermine margin predictability and make it harder to sustain long-term FTE and plant utilization efficiency.
Cashflow VolatilityVolatile free cash flow complicates multi-year investment and dividend policies, and raises refinancing risk during downturns. Irregular cash conversion makes funding capex or sustaining working-capital cycles less predictable, pressuring strategic execution over the medium term.
Hikal Limited News
HIKAL FAQ
What was Hikal Limited’s price range in the past 12 months?
Hikal Limited lowest stock price was ₹145.95 and its highest was ₹307.50 in the past 12 months.
What is Hikal Limited’s market cap?
Hikal Limited’s market cap is ₹27.31B.
When is Hikal Limited’s upcoming earnings report date?
Hikal Limited’s upcoming earnings report date is Nov 18, 2026 which is in 103 days.
How were Hikal Limited’s earnings last quarter?
Hikal Limited released its earnings results on Aug 06, 2026. The company reported -₹0.6 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Hikal Limited overvalued?
According to Wall Street analysts Hikal Limited’s price is currently Overvalued.
Does Hikal Limited pay dividends?
Hikal Limited pays a Semiannually dividend of ₹0.2 which represents an annual dividend yield of 0.45%. See more information on Hikal Limited dividends here
What is Hikal Limited’s EPS estimate?
Hikal Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikal Limited have?
Hikal Limited has 123,300,750 shares outstanding.
What happened to Hikal Limited’s price movement after its last earnings report?
Hikal Limited reported an EPS of -₹0.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.221%.
Which hedge fund is a major shareholder of Hikal Limited?
Currently, no hedge funds are holding shares in IN:HIKAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Rossari Biotech Ltd
―
Solara Active Pharma Sciences Ltd.
―
Supriya Lifescience Limited
―
Wockhardt Limited
―